Articles scientifiques

Implication of body mass index (BMI) on the biological and clinical effects of endocrine therapy plus abemaciclib as neoadjuvant therapy for early breast cancer patients.

Auteurs : Franzoi MA, Lambertini M, Ceppi M, Bruzzone M, de Azambuja E
Année : 2022
Journal : Breast Cancer Res Treat
Volume : 192
Pages : 457-462

Efficacy of tyrosine kinase inhibitors for the treatment of patients with HER2-positive breast cancer with brain metastases: a systematic review and meta-analysis.

Auteurs : Nader-Marta G, Martins-Branco D, Agostinetto E, Bruzzone M, Ceppi M, Danielli L, Lambertini M, Kotecki N, Awada A, de Azambuja E
Année : 2022
Journal : ESMO Open
Volume : 7
Pages : 100501

Assessment of the management of carcinomatous meningitis from breast cancer globally: a study by the Breast International Group Brain Metastasis Task Force.

Auteurs : Razis E, Escudero MJ, Palmieri C, Mueller V, Bartsch R, Rossi G, Gampenrieder SP, Kolberg HC, Zdenkowski N, Pavic M, Connolly RM, Rosset L, Arcuri J, Tesch H, Vallejos C, Retamales J, Musolino A, Del Mastro L, Christodoulou C, Aebi S, Paluch-Shimon S, Gupta S, Ohno S, Macpherson I, Ekholm M, Zaman K, Vidal M, Chakiba C, Fumagalli D, Thulin A, Witzel I, Kotecki N, Gil-Gil M, Linderholm B
Année : 2022
Journal : ESMO Open
Volume : 7
Pages : 100483

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).

Auteurs : Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, Cutter DJ, de Azambuja E, de Boer RA, Dent SF, Farmakis D, Gevaert SA, Gorog DA, Herrmann J, Lenihan D, Moslehi J, Moura B, Salinger SS, Stephens R, Suter TM, Szmit S, Tamargo J, Thavendiranathan P, Tocchetti CG, van der Meer P, van der Pal HJH
Année : 2022
Journal : Eur Heart J Cardiovasc Imaging
Volume : 23
Pages : e333-e465

Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial.

Auteurs : Lopes Cardozo JMN, Drukker CA, Rutgers EJT, Schmidt MK, Glas AM, Witteveen A, Cardoso F, Piccart M, Esserman LJ, Poncet C, van t Veer LJ
Année : 2022
Journal : J Clin Oncol
Volume : 40
Pages : 1335-1345

Anthracyclines in the treatment of patients with early breast cancer.

Auteurs : Guarneri V, de Azambuja E
Année : 2022
Journal : ESMO Open
Volume : 7
Pages : 100461

Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives.

Auteurs : Agostinetto E, Montemurro F, Puglisi F, Criscitiello C, Bianchini G, Del Mastro L, Introna M, Tondini C, Santoro A, Zambelli A
Année : 2022
Journal : Cancers (Basel)
Volume : 14

Endoscopic Bariatric and Metabolic Therapies on Nonalcoholic Fatty Liver Disease: Enough Data to be Considered Effective?

Auteurs : Hadefi A, Gkolfakis P, Devière J
Année : 2022
Journal : Clin Gastroenterol Hepatol
Volume : 20
Pages : 1186-1187

A multi-national survey of experience and attitudes towards commencing home parenteral nutrition for patients with advanced cancer.

Auteurs : Naghibi M, Skinner C, Burden ST, Bozzetti F, Cuerda C, Joly F, Jeppesen P, Lamprecht G, Mundi M, Szczepanek K, Van Gossum A, Wanten G, Pironi L, Lal S
Année : 2022
Journal : Clin Nutr ESPEN
Volume : 47
Pages : 246-251

Timelines to initiate a phase III trial across the globe: a sub-analysis of the APHINITY trial.

Auteurs : Franzoi MA, Procter M, Twelves C, Ponde N, Eiger D, Emond O, Clark E, Parlier D, Guillaume S, Reaby L, de Azambuja E, Bines J
Année : 2022
Journal : Ecancermedicalscience
Volume : 16
Pages : 1379

Editorial: 'All you need is immunotherapy': a new treatment paradigm in sight for early-stage, mismatch repair-deficient/microsatellite instability high gastrointestinal cancers?

Auteurs : Sclafani F, Hendlisz A
Année : 2022
Journal : Curr Opin Oncol
Volume : 34
Pages : 379-381

First-in-man, first-in-class phase I study with the monopolar spindle 1 kinase inhibitor S81694 administered intravenously in adult patients with advanced, metastatic solid tumours.

Auteurs : Schöffski P, Awada A, de la Bigne AM, Felloussi Z, Burbridge M, Cantero F, Colombo R, Maruzzelli S, Ammattatelli K, de Jonge M, Aftimos P, Dumez H, Sleijfer S
Année : 2022
Journal : Eur J Cancer
Volume : 169
Pages : 135-145

Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer.

Auteurs : Loi S, Salgado R, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Munzone E, Drubay D, Lemonnier J, Sotiriou C, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, André F, Denkert C, Piccart-Gebhart M, Roblin E, Michiels S
Année : 2022
Journal : NPJ Breast Cancer
Volume : 8
Pages : 3

Mind the target: human epidermal growth factor receptor 2 in colorectal cancer.

Auteurs : Saude Conde R, Rasschaert G, Bregni G, Hendlisz A, Sclafani F
Année : 2022
Journal : Curr Opin Oncol
Volume : 34
Pages : 382-388

Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study.

Auteurs : Subbiah V, Braña I, Longhi A, Boni V, Delord JP, Awada A, Boudou-Rouquette P, Sarantopoulos J, Shapiro GI, Elias A, Ratan R, Fernandez C, Kahatt C, Cullell-Young M, Siguero M, Zeaiter A, Chawla SP
Année : 2022
Journal : Clin Cancer Res
Volume : 28
Pages : 2762-2770

Patient-reported outcomes in terms of swallowing and quality of life after prophylactic versus reactive percutaneous endoscopic gastrostomy tube placement in advanced oropharyngeal cancer patients treated with definitive chemo-radiotherapy: Swall PEG

Auteurs : Dragan T, Van Gossum A, Duprez F, Lalami Y, Lefebvre Y, Mootassim-Billah S, Beauvois S, Gulyban A, Vandekerkhove C, Boegner P, Paesmans M, Ameye L, Digonnet A, Quiriny M, Dequanter D, Lipski S, Willemse E, Rodriguez A, Carlot S, Karaca Y, Lemort M, Emonts P, Al Wardi C, Van Gestel D
Année : 2022
Journal : Trials
Volume : 23
Pages : 1036

JCOG0603: Are We Really Sure This Was a Negative Trial?

Auteurs : Saude Conde R, Bregni G, Saad E, Hendlisz A, Sclafani F
Année : 2022
Journal : J Clin Oncol
Volume : 40
Pages : 803-805

Molecular oncology: what is needed to speed access to innovative therapies in clinical research?

Auteurs : Gourari K, Awada A, Kotecki N
Année : 2022
Journal : Curr Opin Oncol
Volume : 34
Pages : 575-578

Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Auteurs : Casali PG, Blay JY, Abecassis N, Bajpai J, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Boye K, Brodowicz T, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dufresne A, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Frezza AM, Gasperoni S, Gelderblom H, Gouin F, Grignani G, Haas R, Hassan AB, Hindi N, Hohenberger P, Joensuu H, Jones RL, Jungels C, Jutte P, Kasper B, Kawai A, Kopeckova K, Krákorová DA, Le Cesne A, Le Grange F, Legius E, Leithner A, Lopez-Pousa A, Martin-Broto J, Merimsky O, Messiou C, Miah AB, Mir O, Montemurro M, Morosi C, Palmerini E, Pantaleo MA, Piana R, Piperno-Neumann S, Reichardt P, Rutkowski P, Safwat AA, Sangalli C, Sbaraglia M, Scheipl S, Schöffski P, Sleijfer S, Strauss D, Strauss SJ, Hall KS, Trama A, Unk M, Van De Sande MAJ, van der Graaf WTA, van Houdt WJ, Frebourg T, Gronchi A, Stacchiotti S
Année : 2022
Journal : Ann Oncol
Volume : 33
Pages : 20-33

Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy.

Auteurs : Lambertini M, Fielding S, Loibl S, Janni W, Clark E, Franzoi MA, Fumagalli D, Caballero C, Arecco L, Salomoni S, Ponde NF, Poggio F, Kim HJ, Villarreal-Garza C, Pagani O, Paluch-Shimon S, Ballestrero A, Del Mastro L, Piccart M, Bines J, Partridge AH, de Azambuja E
Année : 2022
Journal : J Natl Cancer Inst
Volume : 114
Pages : 1117-1126